Wire · opportunities
SOTIO Doses First Patient in Phase 1/2 CADENCIA-01 Clinical Trial of SOT109, a CDH17 ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 10 September 2026 · Fusion42 review
SOTIO has dosed the first patient in its Phase 1/2 CADENCIA-01 clinical trial of SOT109, a CDH17-targeting antibody-drug conjugate (ADC) designed to treat advanced colorectal cancer. SOT109 is the only CDH17-targeting ADC granted Fast Track Designation by the U.S. FDA, aiming to rapidly demonstrate safety and early efficacy in a large patient population.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You are seeing new options open for colorectal cancer drug development as SOTIO begins clinical testing of SOT109 with U.S. FDA fast track status. It’s a trigger to revisit your development timelines or partnerships in gastrointestinal cancers.
◆ Coverage
1 source · 9 Sep 2026
◆ Related on Wire
◆ Topics